What's breaking now, across thousands of outlets.
Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
(MedPage Today) -- WASHINGTON -- At 6 months of age, most U.S. infants no longer had detectable levels of maternal neutralizing antibodies for measles, potentially leaving them at risk of an infection…
Less than two years after a wave of administrative layoffs, Mass General Brigham began a new round of job cuts last week that affect clinical and operational programs, according to media reports.
The American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.
